United Therapeutics (NASDAQ:UTHR) CEO Sells $5,261,385.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Friday, May 29th. The shares were sold at an average price of $553.83, for a total value of $5,261,385.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,437,314.79. This represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Stock Up 1.7%

Shares of UTHR opened at $549.47 on Thursday. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The stock has a market cap of $23.33 billion, a PE ratio of 20.28, a price-to-earnings-growth ratio of 1.75 and a beta of 0.57. The firm’s fifty day moving average is $567.74 and its two-hundred day moving average is $518.04.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the company earned $6.63 earnings per share. As a group, research analysts anticipate that United Therapeutics Corporation will post 26.92 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Morgan Stanley set a $516.00 target price on United Therapeutics in a report on Thursday, May 7th. Cantor Fitzgerald boosted their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Raymond James Financial initiated coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, Bank of America lifted their price target on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

Institutional Trading of United Therapeutics

Several institutional investors have recently made changes to their positions in UTHR. Parallel Advisors LLC grew its position in United Therapeutics by 2.8% in the first quarter. Parallel Advisors LLC now owns 1,056 shares of the biotechnology company’s stock worth $626,000 after acquiring an additional 29 shares during the period. NewEdge Advisors LLC increased its stake in United Therapeutics by 24.7% during the first quarter. NewEdge Advisors LLC now owns 2,163 shares of the biotechnology company’s stock worth $1,283,000 after acquiring an additional 428 shares during the last quarter. Janus Henderson Group PLC raised its position in United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after purchasing an additional 70,829 shares during the period. Bull Harbor Capital LLC acquired a new position in shares of United Therapeutics in the 1st quarter valued at $494,000. Finally, Strategic Investment Advisors MI lifted its stake in shares of United Therapeutics by 20.5% in the 1st quarter. Strategic Investment Advisors MI now owns 9,752 shares of the biotechnology company’s stock valued at $5,782,000 after purchasing an additional 1,662 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.